Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

FibroGen licenses anemia candidate to Yamanouchi

Executive Summary

Japanese drug company Yamanouchi Pharmaceutical has licensed exclusive rights in Japan to further develop and sell FibroGen's (fibrotic disease therapies) FG-2216, a small-molecule candidate in clinical trials for anemia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register